ViroPharma is Proud to be a Friend of Rare Disease Day 2013!

Maidenhead, England (ots/PRNewswire) -

--Rare Disease Day takes place on 28 February 2013 and this year's
theme

focuses on 'Rare Disorders without Borders'--

--ViroPharma Incorporated is an international biopharmaceutical
company committed to supporting patients with serious diseases for
which there is an unmet medical

need--

ViroPharma Incorporated , an international biopharmaceutical
company committed to supporting patients with serious diseases for
which there is an unmet medical need, today announced its
participation in the sixth international Rare Disease Day. Rare
Disease Day is coordinated by the European Organisation for Rare
Diseases (EURORDIS) and by the National Organization for Rare
Disorders (NORD) in the US and encourages patient organisations from
across the globe to organise awareness-raising activities around this
year's theme 'Rare Disorders without Borders'.

This year's theme focuses on helping to drive cross-border
cooperation for diseases which affect only a few people in each
country and for which expertise is scarce and scattered. There are
more than 6,000 rare diseases affecting more than 60 million people
in Europe and the US alone.[1] Most of these diseases are genetic,
serious, chronic and debilitating, and 50 percent of rare diseases
touch children.[1]

"ViroPharma is a proud member of EURORDIS and is delighted to be
participating in this year's Rare Disease Day. At ViroPharma, we are
committed to improving the lives of patients and believe in the value
of this year's theme to create a network of solidarity for patients
living with these diseases," said Thierry Darcis, Vice President,
General Manager, ViroPharma, Europe. "We understand the isolation
felt by many people living with rare diseases, and will continue to
deliver solutions that address critical gaps in care for patients
living with few, if any, clinical treatment options."

ViroPharma provides novel treatment solutions for patients living
with rare diseases including hereditary angioedema, adrenal
insufficiency, prolonged, acute, convulsive seizures, and Clostridium
difficile infection.

As part of its commitment to improving the lives of patients with
rare diseases in Europe, ViroPharma sponsors and funds educational
initiatives including:

- The Hereditary Angioedema Burden of Illness Study in Europe
(HAE-BOIS-Europe), an innovative, patient-centric, multi-country study of the
humanistic and economic burden of HAE to address and improve current knowledge gaps
surrounding the condition.
- The PERFECT(TM) (Practices in Emergency and Rescue medication For Epilepsy
managed with Community administered Therapy) Initiative, which aims to document and
communicate first of its kind data on the impact of conflict of policy, guidelines and
actual practice in the care of prolonged, acute, convulsive seizures in infants,
toddlers, children and adolescents in the non-hospital setting.

ViroPharma Incorporated is based in Exton, Pennsylvania, US, and
also has offices in Canada and in eight European countries including
Belgium, France, Germany, Italy, Spain, Sweden, Switzerland and the
United Kingdom. ViroPharma is continuing to grow its footprint and
presence in Europe, and to support this growth set up its first
European subsidiary in 2007, leveraging in Europe the company's
expertise in the development and commercialisation of biotechnology
products, and in business development.

Forward Looking Statements

Certain statements in this press release contain forward-looking
statements that involve a number of risks and uncertainties.
Forward-looking statements provide our current expectations or
forecasts of future events, including our ability to continue to
deliver solutions that address critical gaps in care for patients
living with few, if any, clinical treatment options. There can be no
assurance that we will be successful in our efforts to continue to
deliver solutions in the future. These factors, and other factors,
including, but not limited to those described in our annual report on
Form 10-K for the year ended December 31, 2012 and quarterly reports
on Form 10-Q filed with the Securities and Exchange Commission for
the periods ended March 31, 2012, June 30, 2012 and September 30,
2012, could cause future results to differ materially from the
expectations expressed in this press release. The forward-looking
statements contained in this press release are made as of the date
hereof and may become outdated over time. ViroPharma does not assume
any responsibility for updating any forward-looking statements. These
forward-looking statements should not be relied upon as representing
our assessments as of any date subsequent to the date of this press
release.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercialising novel solutions
for physician specialists to address unmet medical needs of patients
living with diseases that have few, if any, clinical therapeutic
options, including C1 esterase inhibitor deficiency, treatment of
seizures in children and adolescents, adrenal insufficiency, and C.
difficile infection (CDI). Our goal is to provide rewarding careers
to employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with
the patients, advocates, and healthcare professionals we serve.

ViroPharma routinely posts information, including press releases,
which may be important to investors in the investor relations and
media sections of our company's website, http://www.viropharma.com.
The company encourages investors to consult these sections for more
information on ViroPharma and our business.

References

1. Rare Disorders without Borders. Available at: http://www.raredi
seaseday.org/article/rare-disorders-solidarity-has-no-border. Last
accessed January 2013.

ots Originaltext: ViroPharma Incorporated
Im Internet recherchierbar: http://www.presseportal.de

Contact:
VIROPHARMA INCORPORATED Contacts: Thierry Darcis, Vice President,
General Manager, ViroPharma, Europe, Phone: +44-(0)20-7572-1222; Emma
White
(Media Enquiries), PR, Advocacy & Communications Manager, Phone:
+44-(01)628-582732